@article{ref1,
title="Adverse effects of antipsychotics in children and adolescents and their surveillance",
journal="l'Information Psychiatrique",
year="2018",
author="Bousquet, E. and Purper-Ouakil, D.",
volume="94",
number="2",
pages="115-120",
abstract="In France, in the field of child and adolescent psychiatry, antipsychotics are mainly used to treat severe disruptive symptoms, mainly in non-psychotic disorders. The prescription rates of atypical antipsychotics has risen in US and Europe during the past ten years. In adults, numerous papers have been published focusing on the side-effects of atypical antipsychotics. Furthermore, in France their prescription and monitoring have been the subject of specific recommendations. However, no national prescription guidelines are available for children and adolescents. In the first section, we will detail the main side-effects of atypical antipsychotics in the paediatric population such as metabolic syndrome, hyperprolactinemia, and cardiovascular symptoms. Then, we will briefly describe neurological and behavioural side-effects, as well as leukopenia and hypersalivation. Based on CAMESA (Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children) and other studies, we will also provide a guide to prevent and manage the side-effects of antipsychotics. © 2018 John Libbey Eurotext. All rights reserved.; En France, les antipsychotiques sont régulièrement prescrits chez l'enfant et l'adolescent et contrairement à l'adulte, les indications concernent souvent des troubles non-psychotiques. Le taux de prescription des antipsychotiques atypiques a connu une augmentation importante au cours des dix dernières années. Si la surveillance des effets secondaires chez l'adulte fait l'objet de recommandations précises, ce n'est pas le cas, en France, pour les enfants et adolescents. Dans cet article, nous détaillerons les différents effets secondaires des antipsychotiques, en particulier le syndrome métabolique, l'hyperprolactinémie, les effets cardio-vasculaires et nous évoquerons aussi la sédation, l'hypersalivation, la leucopénie, ainsi que les effets secondaires neurologiques et psycho-comportementaux. En nous appuyant sur les recommandations canadiennes de la CAMESA (Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children), nous donnerons une conduite à tenir pour les prévenir et les prendre en charge. © 2018 John Libbey Eurotext. All rights reserved.<p /><p>Language: fr</p>",
language="fr",
issn="0020-0204",
doi="10.1684/ipe.2018.1754",
url="http://dx.doi.org/10.1684/ipe.2018.1754"
}